What Comes Next? Strategies for COVID-19 Vaccine Development
It has been more than a hundred days since Chinese researchers posted the genetic sequence for the SARS-CoV2 virus to a public database, setting off the biggest and fastest race to create vaccines the world has ever seen. One of the defining features of the race is diversity -- of vaccine modalities, types of organizations developing them, and geographic distribution of R&D and manufacturing. So far, at least six vaccines have made it into the clinic. We have reached the end of the beginning: What comes next?
In this exclusive webinar, BioCentury, BioKatalyst and Lonza bring together industry and policy leaders to discuss how to accelerate COVID-19 vaccine development.
Steve Usdin - Washington Editor、BioCentury
- William “Bill” Enright - Director and CEO | Vaccitech, Ltd.
- Nicole Lurie, M.D., M.S.P.H.: Strategic Advisor, CEPI (The Coalition for Epidemic Preparedness Innovation); and former Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services
- Xuefeng YU, Ph.D : Co-founder, Chairman and CEO | CanSino Biologics Inc.